Review on Current Good Manufacturing Practices

Current Good Manufacturing Practices (cGMP) form the backbone of quality assurance in the pharmaceutical industry, ensuring that medicinal products are consistently manufactured and controlled to meet established standards of safety, efficacy, and quality. cGMP encompasses a comprehensive set of regulatory principles covering all stages of pharmaceutical production, including facility design, equipment qualification, material control, validated manufacturing processes, documentation systems, and quality management practices. Regulatory authorities such as the USFDA, WHO, EMA, and CDSCO enforce cGMP requirements to minimize risks that cannot be detected through final product testing alone, including contamination, mix-ups, deviations, and data integrity failures. Over time, cGMP has evolved from a prescriptive compliance model to a science- and risk-based quality system integrating modern concepts such as Quality by Design, Quality Risk Management, Process Analytical Technology, and continuous improvement. Global harmonization of GMP standards through WHO, ICH, PIC/S, and national regulations has facilitated international regulatory convergence and strengthened oversight of global supply chains. This review outlines the fundamental principles, regulatory frameworks, and key components of GMP, with emphasis on quality management, validation, documentation, personnel, premises, and inspection systems. Understanding and effective implementation of cGMP are essential for maintaining regulatory compliance, ensuring consistent product quality, and protecting patient health.